Up-regulation of cyclooxygenase 2 gene expression in XXXX @entity2513 and adenocarcinomas.

@entity1 @entity5 @entity1426 @entity189 @entity14 @entity9859 @entity2247 @entity652 @entity2513
BACKGROUND/AIMS: Several clinical, epidemiological, and animal studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may alter the incidence of @entity14 . A likely target for NSAIDs is cyclooxygenase, a key enzyme in @entity1426 metabolism. Two isoforms of this enzyme have been identified; @entity9859 and @entity2247 . The present study was undertaken to determine if there is differential expression of these isoforms in @entity14 , and, if so, at what stage in malignant transformation this occurs. METHODS: @entity9859 and @entity2247 messenger RNA (mRNA) levels were determined by Northern blot analysis of poly(A)+ RNA isolated from @entity1 @entity14 , @entity652 , and accompanying normal mucosa. RESULTS: There was a marked increase in @entity2247 mRNA levels in 12 of 14 @entity189 (86%) compared with paired normal mucosa. In contrast, there was equivalent intensity of the @entity9859 mRNA transcript between the normal mucosa and @entity5 in all 14 cases. In six pairs of @entity2513 and normal mucosa, three showed up-regulation of @entity2247 in the @entity652 compared with the normal mucosa. Because @entity2247 expression is low to undetectable in normal colorectal mucosa, 14 unpaired @entity652 were examined for @entity2247 expression; a clearly detectable transcript was identified in six (43%). CONCLUSIONS: @entity2247 , but not @entity9859 , gene expression is markedly elevated in most @entity1 @entity14 compared with accompanying normal mucosa. Furthermore, @entity2247 expression seems to be increased in a subset of @entity652 . @entity2247 may provide an attractive therapeutic target in @entity14 .
